Contribution of Corticotropin-Releasing Factor Receptor 1 (CRF1) to Serotonin Receptor 5-HT\(_{2C}\)R Function in Amygdala Neurons in a Neuropathic Pain Model

Guangchen Ji \(^1,2\) and Volker Neugebauer \(^1,2,3,\,*\)

\(^1\) Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79424, USA
\(^2\) Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, Lubbock, TX 79424, USA
\(^3\) Garrison Institute on Aging, Texas Tech University Health Sciences Center, Lubbock, TX 79424, USA

* Correspondence: volker.neugebauer@ttuhsc.edu; Tel.: +806-743-3880; Fax: +806-743-2744

Received: 19 August 2019; Accepted: 1 September 2019; Published: 6 September 2019

Abstract: The amygdala plays a key role in emotional-affective aspects of pain and in pain modulation. The central nucleus (CeA) serves major amygdala output functions related to emotional-affective behaviors and pain modulation. Our previous studies implicated the corticotropin-releasing factor (CRF) system in amygdala plasticity and pain behaviors in an arthritis model. We also showed that serotonin (5-HT) receptor subtype 5-HT\(_{2C}\)R in the basolateral amygdala (BLA) contributes to increased CeA output and neuropathic pain-like behaviors. Here, we tested the novel hypothesis that 5-HT\(_{2C}\)R in the BLA drives CRF1 receptor activation to increase CeA neuronal activity in neuropathic pain. Extracellular single-unit recordings of CeA neurons in anesthetized adult male rats detected increased activity in neuropathic rats (spinal nerve ligation model) compared to sham controls. Increased CeA activity was blocked by local knockdown or pharmacological blockade of 5-HT\(_{2C}\)R in the BLA, using stereotaxic administration of 5-HT\(_{2C}\)R short hairpin RNA (shRNA) viral vector or a 5-HT\(_{2C}\)R antagonist (SB242084), respectively. Stereotaxic administration of a CRF1 receptor antagonist (NBI27914) into the BLA also decreased CeA activity in neuropathic rats and blocked the facilitatory effects of a 5-HT\(_{2C}\)R agonist (WAY161503) administered stereotaxically into the BLA. Conversely, local (BLA) knockdown of 5-HT\(_{2C}\)R eliminated the inhibitory effect of NBI27914 and the facilitatory effect of WAY161503 in neuropathic rats. The data suggest that 5-HT\(_{2C}\)R activation in the BLA contributes to neuropathic pain-related amygdala (CeA) activity by engaging CRF1 receptor signaling.

Keywords: serotonin; CRF; amygdala neurons; neuropathic pain; short hairpin RNA (shRNA); hyperactivity

1. Introduction

Serotonin (5-HT) plays an important role in pain modulation and can have facilitatory and inhibitory effects depending on the site of action in the nervous system, cell type, and receptor subtype and affinity [1–4]. The 14 5-HT receptor subtypes are classified into seven groups based on their structural and functional characteristics [5–7]. Selective serotonin reuptake inhibitors (SSRIs) are commonly used in the treatment of major depression and related disorders, and they can relieve neuropathic pain but have limited efficacy and adverse side effects [8–12].

The Gq-coupled 5-HT\(_{2C}\) receptor (5-HT\(_{2C}\)R) has been implicated in adverse (anxiogenic) effects of SSRIs [13] and their inconsistent efficacy in neuropathic pain [14]. Preclinical and clinical studies...
suggest that pharmacological activation of 5-HT2C R has anxiogenic effects, while 5-HT2C R antagonists are anxiolytic (see references in [15]). Several lines of evidence point to the amygdala, a limbic system structure that plays a key role in emotions and affective disorders [16], as an important site of 5-HT2C R-mediated anxiogenic effects. In the amygdala, 5-HT2C R messenger ribonucleic acid (mRNA) and protein can be found, particularly in its basolateral nucleus (BLA) [17,18]. The BLA receives serotonergic input from the dorsal raphe nucleus [19,20], and 5-HT release into the BLA, but not central nucleus (CeA), is increased in aversive states [19,21–23]. Overexpression of 5-HT2C R is found in glutamatergic neurons in the amygdala and other brain areas in calmodulin-dependent protein kinase IIα-2C receptor (CaMKIIα–2CR) transgenic mice [24], and increased 5-HT2C R expression in the BLA using recombinant adenovirus-containing 5-HT2C R sense sequence [25] resulted in increased anxiety-like behaviors in the elevated plus maze (EPM) and open field test (OFT), which was independent of hypothalamic–pituitary–adrenal (HPA) axis activity [25]. Conversely, 5-HT2C R knockout mice showed decreased anxiety-like behaviors and decreased neurochemical activation (c-Fos immunoreactivity) in the CeA [26]. Pharmacologic activation of 5-HT2C R in the BLA, but not CeA, had anxiogenic effects in the elevated T-maze, light-dark test and OFT [15,27], and induced ultrasonic vocalizations [27]. A 5-HT2C R antagonist (SB242084) in the BLA had anxiolytic effects and blocked anxiogenic effects of local 5-HT or systemic SSRIs in the elevated T-maze [28]. A 5-HT2A2C R antagonist (ritanserin) prevented anxiogenic effects of a systemic 5-HT2C R agonist on the EPM [29].

The amygdala also plays an important role in emotional-affective aspects of pain and pain modulation [30–32]. Synaptic plasticity in the amygdala circuitry composed of CeA neurons and their inputs from the spino-parabrachio-amygdaloid pathway and from the BLA network, has been mechanistically linked to pain behaviors in models of acute [33–42] and chronic pain [43–46]. Pain-related synaptic plasticity results in increased background and evoked activity of CeA neurons [38,45,47–55] through a mechanism that involves activation of corticotropin-releasing factor 1 (CRF1) receptors in the CeA and BLA [36,48,56]. Recent evidence suggests that 5-HT in the amygdala contributes to pain-related neuronal activity changes and behaviors, and these effects are mediated through the 5-HT2C receptor. 5-HT2C R has been linked to the neurochemical activation of CeA neurons in an anxiety model (OFT) mentioned previously [26], and 5-HT2C R can facilitate synaptic plasticity in BLA pyramidal neurons [57]. 5-HT can also decrease BLA output by direct 5-HT1A R-mediated inhibition of glutamatergic principal neurons [58], by HT1B R-mediated inhibition of their glutamatergic drive [59] or by 5-HT2R-mediated activation of BLA interneurons [19,58,60]. Recent studies from our group found that knockdown of 5-HT2C R in the BLA decreased the excitatory drive of CeA neurons and attenuated nociceptive and aversive affective behaviors in a neuropathic pain model [45]. A 5-HT2CR antagonist in the BLA, but not CeA, enabled a systemically applied SSRI to inhibit pain behaviors in an arthritis model [61].

The present study tested the novel hypothesis that 5-HT2C R in the BLA contributes to neuropathic pain-related hyperactivity in the amygdala output region (CeA) through activation of CRF1 receptors. The results suggest that CRF1 receptor activation downstream of 5-HT2C R contributes to increased activity of CeA neurons in a neuropathic pain model.

2. Results

The experiments described here were designed to analyze the interaction between serotonin receptor 5-HT2C R in the basolateral amygdala (BLA) and corticotropin-releasing factor receptor CRF1 signaling downstream of 5-HT2C R and their contribution to the increased activity of the central amygdala (CeA) neurons in a neuropathic pain model. Single-unit recordings of CeA neurons in sham control rats and in neuropathic rats (spinal nerve ligation model, SNL) were used. Extracellular single-unit recordings were made from 44 CeA neurons (n = 15 neurons in 9 sham rats; n = 29 neurons in 11 SNL rats) in anesthetized (isoflurane) adult male rats (Figure 1) as described in the materials and methods section. Neurons were selected that had a receptive field in the left hindpaw (side of sham or SNL surgery), and responded more strongly to brief noxious than innocuous test
stimuli; these are so-called “multireceptive” (MR) neurons according to our classification of amygdala neurons [31,45,48,62]. The general experimental protocol was as follows: Induction of pain model (spinal nerve ligation) or sham surgery (Day 0), 5-HT2CR short hairpin RNA (shRNA)-enhanced green fluorescence protein (eGFP) for knockdown or shRNA-eGFP (control) adeno-associated viral vector (AAV) vectors injections (Day 14), and electrophysiological experiments with or without drug applications (Day 28).

![Histologically verified recording sites of 44 neurons in the central nucleus of the amygdala (CeA).](image)

**Figure 1.** Histologically verified recording sites of 44 neurons in the central nucleus of the amygdala (CeA). The boundaries of the different amygdala nuclei were easily identified under the microscope. Diagrams show the central nucleus and its medial (CeM), lateral (CeL), and latero-capsular (CeLC) subdivisions in coronal sections at different levels posterior to bregma (−2.30 to −2.80). Symbols show the positions of the tips of recording electrodes in the CeA based on electrolytic lesions (see the materials and methods section) in spinal nerve ligation (SNL) (red) and sham (blue) rats. Scale bars, 500 µm.

2.1. 5-HT2CR Knockdown in the BLA Inhibits Activity of CeA Neurons in Neuropathic Rats

For local (BLA) knockdown of 5-HT2CR, recombinant AAV2 vectors expressing a short hairpin RNA (shRNA) directed at the 5-HT2CR or a control hairpin were used [45,63,64]. Either 5-HT2CR or a control shRNA-eGFP AAV2 vector was injected stereotaxically into the BLA two weeks after neuropathic or sham surgery, as described in the materials and methods section. Electrophysiology studies were done two weeks after viral vector injection. Compared to CeA neurons in sham controls treated with a control vector (n = 18 neurons), CeA neurons in SNL rats treated with control vector (n = 10 neurons) showed significantly (p < 0.05, ANOVA with Bonferroni post hoc tests) increased background activity and responses to innocuous and noxious stimuli (mechanical compression of the hindpaw with a calibrated forceps, see the materials and methods section; Figure 2G). Individual examples are shown in Figure 2A–C. There was also a significant increase in burst-like activity (Figure 2H; p < 0.01) and irregular firing (Figure 2I; p < 0.001, ANOVA with Bonferroni post hoc tests) of CeA neurons in SNL rats (n = 10 neurons) compared to sham controls (n = 14 neurons). Individual examples are shown in Figure 2D–F. Details of the analysis of neuronal activity are described in the materials and methods section. CeA neurons in SNL rats with local 5-HT2CR knockdown in
the BLA (n = 6 neurons) showed significantly lower background and evoked activity (Figure 2G; p < 0.01), less burst-like activity (Figure 2H; p < 0.01), and less irregular firing (Figure 2I; p < 0.001, ANOVA with Bonferroni post hoc tests) compared to CeA neurons in control vector treated SNL rats. Our previous study showed that 5-HT$_{2C}$R knockdown had no effect in sham controls [45]. The results of the present study validate the neuropathic pain-related neuronal changes and the effectiveness of 5-HT$_{2C}$R knockdown observed in our previous study [45], allowing us to use the knockdown strategy to link 5-HT$_{2C}$R and CRF1 receptor function and to confirm the selectivity of pharmacological agents tested here.

**Figure 2.** 5-HT$_{2C}$R knockdown in the basolateral amygdala (BLA) inhibits CeA neuronal activity in a neuropathic pain model. (A–C) Examples of individual CeA neurons (three different neurons). Peristimulus time histograms (PSTHs) show the number of action potentials (spikes) per second. Innocuous and noxious stimuli (compression of the hindpaw for 15 s) are indicated by horizontal lines. (D–F) Joint interspike interval (ISI) plots (previous ISI against the subsequent ISI) detected burst activity, indicated by the rectangular insets (dots within the dashed red lines represent the first spike in a burst). Examples of individual CeA neurons (three different neurons). (A,D) CeA neuron recorded in a sham rat injected with control vector into the BLA. (B,E) CeA neuron in an SNL rat with control vector injected into the BLA. (C,F) CeA neuron in an SNL rat with 5-HT$_{2C}$R knockdown in BLA. (G–I) Bar histograms showing mean ± SE for the sample of neurons. (G) Background activity and net evoked responses to innocuous and noxious stimuli increased significantly in (control vector treated) SNL rats.
(n = 10 neurons) compared to (control vector treated) shams (n = 18 neurons). * p < 0.05, ANOVA with Bonferroni post hoc tests. 5-HT2C-R short hairpin RNA (shRNA) vector injected into the BLA (n = 6 neurons) decreased background and evoked activity in SNL rats significantly compared to control vector-treated SNL rats. ** p < 0.01, ANOVA with Bonferroni post hoc tests. (H) Burst activity of CeA neurons was significantly higher in SNL rats (n = 10 neurons) compared with shams (n = 14 neurons). ** p < 0.01, ANOVA with Bonferroni post hoc tests. 5-HT2C-R knockdown in the BLA decreased background and evoked activity in SNL rats significantly compared to control vector-treated SNL rats. (** p < 0.01, ANOVA with Bonferroni post hoc tests. (I) Irregular firing (CV2) of CeA neurons was significantly increased in SNL rats (n = 10 neurons) compared with shams (n = 14 neurons). *** p < 0.001, ANOVA with Bonferroni post hoc tests. 5-HT2C-R knockdown in the BLA decreased CV2 in CeA neurons in SNL rats (n = 6 neurons) significantly compared to control vector treated SNL rats (n = 14 neurons). +++ p < 0.001, ANOVA with Bonferroni post hoc tests. (G–I) Legend for bar histograms in G also applies to H and I.

2.2. Inhibitory Effects of Antagonists for 5-HT2C-R and CRF1 Receptor on CeA Neurons in Neuropathic Rats

The effects of selective antagonists for 5-HT2C-R (SB242084) and the CRF1 receptor (NBI27914) were tested in neuropathic rats 2 weeks after control shRNA was injected into the BLA (Figure 3). Control shRNA was used to allow the comparison with 5-HT2C-R knockdown effects shown in Figure 4. Background activity and evoked responses of CeA neurons to innocuous (100 g/6 mm²) and noxious (500 g/6 mm²) stimulation of the left hindpaw were recorded before (predrug control) and after drug administration. Administration of SB242084 (100 µM, concentration in microdialysis fiber; 15 min) into BLA in SNL rats decreased background activity and evoked responses of CeA neurons significantly (n = 8 neurons, p < 0.01–0.05, compared to predrug, paired t-test; Figure 3C). The activity of an individual CeA neuron was shown before (control, ACSF; Figure 3A) and during antagonist administration (Figure 3B). Administration of NBI27914 (100 µM, concentration in microdialysis fiber; 15 min) into the BLA also decreased background activity and evoked responses significantly (n = 5 neurons, p < 0.05, compared to predrug, paired t-test; Figure 3F). An individual example is shown before (Figure 3D) and during (Figure 3E) antagonist administration.

2.3. 5-HT2C-R Knockdown Eliminates the Inhibitory Effects of Antagonists for 5-HT2C-R and CRF1 Receptor on CeA Neurons in Neuropathic Rats

CeA neurons were recorded in neuropathic rats 2 weeks after 5-HT2C-R shRNA was injected into the BLA to knock down 5-HT2C-R, i.e., 4 weeks post SNL surgery. In contrast to SNL rats without 5-HT2C-R knockdown (see Figure 3), administration of SB242084 (100 µM, concentration in microdialysis fiber; 15 min) into the BLA of SNL rats with 5-HT2C-R knockdown had no significant effect on background activity and on evoked responses of CeA neurons (n = 6 neurons, p > 0.05, compared to predrug, paired t-test; Figure 4C). Activity of an individual CeA neuron before (control, ACSF) and during antagonist administration is shown in Figure 4A,B. Administration of a CRF1 receptor antagonist (NBI27914, 100 µM, concentration in microdialysis fiber; 15 min) into the BLA also had no effect on background and evoked activity of CeA neurons recorded in SNL rats with 5-HT2C-R knockdown (n = 6 neurons, Figure 4F). Figure 4D,E shows an individual example before (control, ACSF) and during antagonist administration. The data suggest that 5-HT2C-R knockdown in BLA eliminated the inhibitory effects of antagonists for 5-HT2C and CRF1 receptors on CeA neurons in neuropathic pain.
Figure 3. Inhibitory effects of antagonists for 5-HT$_{2C}$R (SB242084) and corticotropin-releasing factor 1 (CRF1) receptor (NBI27914) on CeA neurons in a neuropathic pain model. CeA neurons were recorded in SNL rats 2 weeks after control shRNA was injected into the BLA, i.e., 4 weeks post SNL surgery. Background activity and evoked responses to innocuous and noxious stimulation of the left hindpaw are shown. (A, B) SB242084 administered into BLA (100 µM concentration in microdialysis fiber; 15 min; (B)) decreased background and evoked responses compared to predrug control (ACSF; (A)) in an individual CeA neuron. Top traces, peristimulus time histograms (PSTHs) showing the number of action potentials (spikes) per second. Middle traces, original oscilloscope traces. Bottom traces, filtered spikes matched to a preset template that were counted to generate PSTH values. (C) Summary of the significant inhibitory effects, SB242084 effects (n = 8 neurons). *, ** p < 0.05, 0.01, paired t-test compared to predrug control (ACSF), respectively. (D, E) NBI27914 (100 µM concentration in microdialysis fiber; 15 min; (E)) decreased background and evoked responses compared to predrug control (ACSF; (D)). Same display as in (A, B). (F) Summary of the significant effects of NBI27914 (n = 5 neurons). * p < 0.05, paired t-test compared to predrug control (ACSF).

2.4. Excitatory Effects of a 5-HT$_{2C}$R Agonist (WAY161503) Are Blocked by a CRF1 Receptor Antagonist (NBI27914) in Neuropathic Rats

CeA neurons were recorded in neuropathic rats 4 weeks after SNL surgery. Administration of a 5-HT$_{2C}$R agonist (WAY161503; 100 µM, concentration in microdialysis fiber; 15 min) into the BLA increased responses of CeA neurons to innocuous (100 g/6 mm$^2$) and noxious (500 g/6 mm$^2$) stimulation of the left hindpaw (Figure 5). A selective CRF1 receptor antagonist (NBI27914; 100 µM, concentration in microdialysis fiber) reversed the effect of WAY161503. An individual neuron is shown in Figure 5A–D. Data are summarized in Figure 5E. The facilitatory effects of the 5-HT$_{2C}$R agonist on the responses to innocuous and noxious stimuli, but not background activity, were significant, and the CRF1 receptor antagonist inhibited the facilitation significantly (n = 5 neurons; background activity,
p > 0.05, F(2,8) = 2.686; innocuous, p < 0.01, F(2,8) = 9.818; noxious, p < 0.01, F(2,8) = 9.914; repeated measures ANOVA). In contrast, WAY161503 had no significant effect in sham rats (p > 0.05, paired t-test; n = 5 neurons; background activity, 1.8 ± 0.69 Hz, predrug; 1.9 ± 0.69 Hz, agonist; responses to innocuous stimuli, 2.1 ± 0.67 Hz, predrug; 2.4 ± 0.93 Hz, agonist; and noxious stimuli, 3.5 ± 1.4 Hz, predrug; 3.3 ± 1.4 Hz, agonist).

Figure 4. 5-HT2C receptor knockdown eliminated the inhibitory effect of antagonists for 5-HT2C (SB242084) and CRF1 receptors (NBI27914) on CeA neurons in a neuropathic pain model. CeA neurons were recorded in SNL rats 2 weeks after 5-HT2C shRNA was injected into the BLA, i.e., 4 weeks post SNL surgery. Background activity and evoked responses to innocuous (100 g/6 mm²) and noxious (500 g/6 mm²) stimulation of the left hindpaw are shown. (A, B) SB242084 (100 µM concentration in microdialysis fiber; 15 min; (B)) had no effect in an individual CeA neuron compared to predrug control (ACSF; (A)). Same display as in Figure 3. (C) Summary of lack of significant effects of SB242084 on CeA neurons (n = 6 neurons; p > 0.05, paired t-test compared to predrug). (D, E) NBI27914 administered into BLA (100 µM concentration in microdialysis fiber; 15 min; (E)) had no effect in an individual CeA neuron compared to predrug control (ACSF, (D)). (F) Summary of the lack of significant effects of NBI27914 on CeA neurons (n = 6 neurons; n.s., not significant, p > 0.05, paired t-test compared to predrug).
2.5. Excitatory Effects of a 5-HT\textsubscript{2C}R Agonist (WAY161503) Are Prevented by a CRF1 Receptor Antagonist (NBI27914) in Neuropathic Rats

Next, we determined if pre-treatment with a CRF1 receptor antagonist would prevent the 5-HT\textsubscript{2C}R agonist effect. CeA neurons were recorded in SNL rats 4 weeks after SNL surgery. Administration of a selective CRF1 receptor antagonist (NBI27914; 100 \( \mu \text{M} \) concentration in microdialysis fiber) into the BLA decreased background and evoked activity of CeA neurons (Figure 6). In the presence of the CRF1 receptor antagonist, a 5-HT\textsubscript{2C}R agonist (WAY161503) had no effect on background activity and evoked responses of CeA neurons. An individual neuron is shown in Figure 6A–D. Data are summarized in Figure 6E. The inhibitory effects of WAY161503 alone (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min) and reversal by NBI27914 (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min) administered into the BLA (A–C) Peristimulus time histograms show action potentials (spikes) per second in one individual CeA neuron before (A) and during application of WAY161503 alone (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min; (B)) and during coapplication of WAY161503 with NBI27914 (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min; (C)) into BLA. (D) Time course data showing the increase in activity by WAY161503 (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min) and reversal by NBI27914 (100 \( \mu \text{M} \) concentration in microdialysis fiber; 15 min) administered into the BLA. (E) Summary of drug effects in SNL rats (\( n = 5 \) neurons). n.s., not significant; *, ** \( p < 0.05 \), 0.01 Bonferroni post hoc tests, respectively (repeated measures ANOVA, see results section).
Figure 6. A CRF1 receptor antagonist (NBI27914) prevented the effects of a 5-HT\textsubscript{2C}R agonist (WAY161503) in neuropathic pain. CeA neurons were recorded in SNL rats 4 weeks after SNL surgery. Background activity and evoked responses to innocuous (100 g/6 mm\textsuperscript{2}) and noxious (500 g/6 mm\textsuperscript{2}) stimulation of the left hindpaw are shown. (A–C) Peristimulus time histograms show action potentials (spikes) per second in one individual CeA neuron before (ACSF; (A)) and during application of NBI27914 (100 µM concentration in microdialysis fiber; 15 min; (B)) and during coapplication of NBI27914 with WAY161503 (100 µM concentration in microdialysis fiber; 15 min; (C)) into BLA. (D) Time course data show the inhibitory effect of NBI27914 (100 µM concentration in microdialysis fiber) and lack of excitatory effect of WAY161503 (100 µM concentration in microdialysis fiber; 15 min) administered into the BLA. (E) Summary of drug effects (n = 6 neurons). Inhibitory effects of NBI27914 were significant, and continued during co-administration of WAY161503; and WAY161503 had no significant effect. *, ** \(p < 0.05, 0.01\), Bonferroni post hoc tests, respectively (repeated measures ANOVA, see results section).

2.6. Excitatory Effects of a 5-HT\textsubscript{2C}R Agonist (WAY161503) Are Eliminated by 5-HT\textsubscript{2C}R Knockdown in Neuropathic Rats

CeA neurons were recorded in SNL rats 2 weeks after 5-HT\textsubscript{2C}R shRNA was injected into the BLA to knock down 5-HT\textsubscript{2C}R, i.e., 4 weeks post SNL surgery. In contrast to neuropathic rats without knockdown (Figures 5 and 6), WAY161503 (100 µM concentration in microdialysis fiber; 15 min) had no significant facilitatory effects (\(p > 0.05\), paired \(t\)-test; \(n = 6\) neurons) in SNL rats with 5-HT\textsubscript{2C}R knockdown (Figure 7C). Activity of an individual CeA neuron before (control, ACSF) and during agonist administration is shown in Figure 7A,B.
knockdown (Figure 7C). Activity of an individual CeA neuron before (control, ACSF) and during agonist administration is shown in Figure 7A,B.

Figure 7. Excitatory effects of a 5-HT$_{2C}$R agonist (WAY161503) were eliminated by 5-HT$_{2C}$R knockdown in neuropathic rats. CeA neurons were recorded in SNL rats 2 weeks after 5-HT$_{2C}$R shRNA was injected into the BLA, i.e., 4 weeks post SNL surgery. Background activity and evoked responses to innocuous (100 g/6 mm$^2$) and noxious (500 g/6 mm$^2$) stimulation of the left hindpaw are shown. (A,B) WAY161503 (100 µM concentration in microdialysis fiber; 15 min; (B)) had no effect in an individual CeA neuron compared to predrug control (ACSF; (A)). Same display as in Figures 3 and 4. (C) Summary of lack of significant facilitatory effects of WAY161503 on CeA neurons (n = 6 neurons; p > 0.05, paired t-test compared to predrug).

3. Discussion

Serotonin 5-HT$_{2C}$R has emerged as an important target for the treatment of neurological and psychiatric disorders, including substance use disorders, schizophrenia, impulsive/compulsive disorders, anxiety, depression, and epilepsy. 5-HT$_{2C}$R can modulate multiple neurotransmitter systems to modulate network functions and behaviors, and effects may depend on the site of action in the nervous system, differential coupling to intracellular signaling pathways, and condition/disease (see reference [65]).

While there is evidence for pro-nociceptive and anxiogenic effects of 5-HT$_{3C}$R (see the introduction section and [66]), its role in pain modulatory centers in the brain is an understudied area of research. Evidence from our recent study suggests that 5-HT$_{2C}$R in the basolateral amygdala (BLA) increases neuronal activity in the amygdala output region (central nucleus, CeA) to drive neuropathic pain-like behaviors [45]. Knockdown of 5-HT$_{2C}$R in the BLA decreased the excitatory drive of CeA neurons more strongly than synaptic inhibition and attenuated nociceptive and aversive behaviors in a neuropathic pain model, whereas 5-HT$_{2C}$R knockdown in sham controls only decreased synaptic inhibition without behavioral effects [45]. Further supporting an important role of 5-HT$_{2C}$R in
amygdala-dependent behaviors, a 5-HT2CR antagonist in the BLA, but not CeA, enabled a systemic SSRI to inhibit pain behaviors in an arthritis model [61].

The present study advanced this line of research by testing the novel hypothesis that the contribution of 5-HT2C R in the BLA to neuropathic pain-related hyperactivity in the CeA involves activation of CRF1 receptors. Increased CeA activity was blocked by local knockdown of 5-HT2C R in the BLA (Figure 2) or by a 5-HT2C R antagonist (SB242084) administered into the BLA (Figure 3). Stereotaxic administration of a 5-HT2C R agonist (WAY161503) had facilitatory effects in the neuropathic pain model (Figure 5) but not in sham controls (see Section 2.4), which is consistent with the results of our previous brain slice physiology study showing a contribution of 5-HT2C R in the BLA to excitatory transmission in the pain model but synaptic inhibition under control conditions [45].

Next, we addressed the potential contribution of CRF1 receptors. The amygdala (CeA but not BLA) is a major site of CRF expression, showing the highest content of CRF neurons outside the hypothalamus [67–71]. CRF1 receptors are expressed in the CeA and BLA [72] and play an important role in pain-related amygdala plasticity and amygdala-mediated behaviors in models of arthritic, visceral, and neuropathic pain [36,48,56,73–77].

There is evidence to suggest that in the amygdala CRF acts downstream of 5-HT2C R [26]. Elimination of 5-HT2C R in knockout mice blocked the neurochemical (FOS) activation of CRF CeA neurons in response to an anxiogenic stimulus (open field) [26]. The midbrain dorsal raphe nucleus is a major source of serotonergic input to the amygdala, and 5-HT axons innervate pyramidal cells and interneurons in the BLA, but not CeA [20,78–80]. 5-HT2C R is expressed postsynaptically to serotonergic axons [17,18]. Pharmacologic activation of 5-HT2C R in the BLA, but not CeA, increased measures of anxiety-like behaviors in the elevated plus maze [81], elevated T-maze [15], light-dark transition test [15], and open-field test [82]. These lines of evidence point to the BLA as an important site of 5-HT2C R action to modulate CeA function.

In the present study, we recorded from CeA neurons to determine their modulation by 5-HT2C R through CRF1 receptors in the BLA. The BLA receives polymodal, including nociceptive, information and provides synaptic excitation as well as feedforward inhibition to CeA neurons [30–32,83]. While the CeA is generally considered the output region for major amygdala function [70], including emotional-affective aspects of pain and pain modulation [30–32,84], the BLA has also been implicated in top-down pain modulation [85,86], aversive affective aspects of pain [83], and cognitive deficits associated with pain [56]. Our recent study showed a 5-HT2C R-driven shift towards excitatory influences of the BLA on CeA activity and behaviors in a neuropathic pain model [45].

Here, we report that a CRF1 receptor antagonist administered into the BLA blocks or prevents (Figures 5 and 6) the increase of CeA neuronal activity by a 5-HT2C R agonist (WAY161503) administered into the BLA in the neuropathic pain model (Figure 5), suggesting that 5-HT2C R activation generates endogenous activation of CRF1 receptors, presumably through the activation of CRF neurons in the CeA [67–71] and release of CRF into the CeA and BLA. 5-HT2C R knockdown in the BLA eliminated the agonist effects (Figure 7), confirming that they were mediated by 5-HT2C R. 5-HT2C R knockdown in the BLA of neuropathic rats also blocked the inhibitory effects of a CRF1 receptor antagonist (Figure 4), providing further support of our hypothesis that 5-HT2C R activation in the BLA contributes to neuropathic pain-related amygdala (CeA) activity by engaging CRF1 receptor signaling.

As a note of caution, we did not confirm the effects of 5-HT2C R knockdown in this study. The viral vector that we used has been validated thoroughly [63,64] and we showed previously that focal (BLA) injection of AAV-expressing 5-HT2C R shRNA, but not control shRNA, decreased 5-HT2C R mRNA and immunoreactivity [45]. Using the same tools, assays, and protocol, there was no reason to expect different results. Another consideration is drug application by microdialysis. This technique offers several advantages, such as avoidance of volume effect and steady state application, but the exact tissue concentration can only be estimated (see the materials and methods section). We selected concentrations based on our previous studies using antagonists for the CRF1 receptor (NBI27914) [36,56,87,88] and 5-HT2C R (SB242084), which was supported by data in the literature (see the materials and methods...
Importantly, local (BLA) knockdown of 5-HT\textsubscript{2C}R eliminated the inhibitory effect of SB242084 (Figure 4) and the facilitatory effects of a 5-HT\textsubscript{2C}R agonist (WAY161503) (Figure 7) in neuropathic rats, which strongly argues for specific actions on 5-HT\textsubscript{2C}R. Finally, we did not perform off-site drug injections in this study. However, we showed previously that 5-HT\textsubscript{2C}R knockdown in the BLA, but not the CeA, had inhibitory neuronal and behavioral effects [45]. Data in the literature also support an action of 5-HT\textsubscript{2C}R in the BLA, but not the CeA (see the introduction and discussion sections). In this study, 5-HT\textsubscript{2C}R knockdown in the BLA blocked the effects of pharmacological agents (Figures 4 and 7). While CRF1 receptors are expressed and functional both in BLA and CeA [36,56], off-site injections of CRF or CRF1 and CRF2 receptor antagonists into the neighboring striatum had no effect [36,87]. These findings suggest that 5-HT\textsubscript{2C}R in the BLA and CRF1 in the amygdala contributed to the observed effects on the CeA neurons, but the site of action of CRF1 in the BLA versus CeA could not be distinguished here.

In summary, the new results of this study link CRF1 receptor activation to 5-HT\textsubscript{2C}R in the BLA in a neuropathic pain model. The 5-HT\textsubscript{2C}R and CRF1 receptor interaction results in increased activity of CeA neurons. Our previous work showed an important role of 5-HT\textsubscript{2C}R in the BLA for CeA neuronal hyperactivity in neuropathic pain. The new data show that 5-HT\textsubscript{2C}R knockdown eliminates the inhibitory effects of a CRF1 receptor antagonist and the facilitatory effects of a 5-HT\textsubscript{2C}R agonist, and that the agonist effects are also blocked or prevented by a CRF1 receptor antagonist.

4. Materials and Methods

4.1. Animals

Male Sprague Dawley rats (250–350 g, Harlan Laboratories) were housed in a temperature-controlled room in the animal facility under a 12 h light/dark cycle with unrestricted access to water and food. On the day of the experiment, rats were transferred to the laboratory and allowed to acclimate for at least 1 h. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Texas Tech University Health Sciences Center, TX, USA (Protocol 14006, approved 23 June 2014) and conformed to the guidelines of the International Association for the Study of Pain and of the National Institutes of Health.

4.2. Neuropathic Pain Model

The spinal nerve ligation (SNL) model [89] was used as described in our previous study [45]. Rats were anesthetized with isoflurane (3–4% induction, 2% maintenance) while the L5 spinal nerve was tightly ligated using 6–0 silk, using sterile techniques. In the sham control group, the spinal nerve was exposed but not ligated. The SNL model generates stable neuropathic pain behaviors that last for at least 4–5 weeks [45]. While the experimenter was not blinded to the experimental condition for technical reasons, the analysis involved a blinded experimenter.

4.3. Viral Vector for 5-HT\textsubscript{2C}R Knockdown

For local (basolateral amygdala, BLA) knockdown of 5-HT\textsubscript{2C}R, recombinant AAV2 vectors expressing a short hairpin RNA (shRNA) directed at the 5-HT\textsubscript{2C}R or a control hairpin were used [45,63,64]. Vectors were obtained from the Vector Core at the University of North Carolina at Chapel Hill (UNC Vector Core). 5-HT\textsubscript{2C}R or control shRNA-eGFP AAV2 vector (1 µL) was injected stereotaxically into the BLA of rats anesthetized with isoflurane (3–4% induction, 2% maintenance; precision vaporizer, Harvard Apparatus), two weeks after neuropathic or sham surgery. The following coordinates were used: 2.5 mm caudal to bregma, 4.8 mm lateral, 8.0–8.5 mm depth. Two weeks after neuropathic surgery, control shRNA-eGFP AAV vector (1 µL) or 5-HT\textsubscript{2C}R shRNA-eGFP AAV vector (for 5-HT\textsubscript{2C}R knockdown; 1 µL) was injected stereotaxically into the BLA. Rats recovered for 2 weeks before the electrophysiological recordings to allow for stable transgene expression. 5-HT\textsubscript{2C}R knockdown was validated with qPCR, western blot analysis and immunohistochemistry in our previous study [45].
4.4. Systems Electrophysiology

Extracellular single-unit recordings were made from neurons in the laterocapsular division of the CeA (CeLC) as described previously [90], for recent references see [45]. Rats were anesthetized with isoflurane (3–4% induction, 2% maintenance). Core body temperature was maintained at 37 °C with a homeothermic blanket system. The animal was mounted in a stereotaxic frame (Kopf Instruments) and a craniotomy was performed at the sutura frontoparietalis level to allow the insertion of the recording electrode and microdialysis probe for drug or vehicle administration.

Neurons were recorded with glass-insulated carbon filament electrodes (4–6 MΩ) using the following coordinates: 2.3–2.8 mm caudal to bregma, 3.8–4.2 mm lateral to midline, depth 7–8 mm. The recorded signals were amplified, band-pass filtered (300 Hz to 3 kHz), displayed on an analog oscilloscope, and processed by an interface (1401 Plus; CED). Spike2 software (version 4; CED) was used for spike sorting, data storage, and analysis of neuronal activity. Spike size and configuration were monitored continuously. For each neuron, a spike template was created during a 5 min baseline recording period. Only those neurons were included in the study that showed a spike configuration that matched the preset template and could be clearly discriminated from activity in the background throughout the experiment. Neurons were identified by monitoring background activity and responses to search stimuli, i.e., compression of the hindpaw at innocuous (100 g/6 mm²) and noxious (500 g/6 mm²) intensities with calibrated forceps. Noxious stimuli were used sparingly. Neurons included in this study had a receptive field in the hindpaw (L5 territory) and were activated more strongly by noxious than innocuous mechanical stimuli. One neuron was recorded per animal to allow for verification of the recording with electrolytic lesion at the end of the experiment (see “verification of recording site”) and to avoid confounding effects of drug applications.

4.5. Neuronal Activity Analysis

Background activity (in the absence of intentional stimulation) was measured for 5 min and evoked activity was recorded during brief (15 s) innocuous and noxious test stimuli applied to the hindpaw. Net evoked activity was calculated by subtracting background activity (mean value of 1–3 min) preceding the stimulus from the total activity during stimulation. Neuronal activity was expressed as spikes per second. Spike2 software burst analysis script was used to analyze interspike interval (ISI) distribution and burst-like activity for each CeA neuron, as described previously [45]. Burst-like activity was defined as in our previous study [45]—a silent period of at least 100 ms preceded the first spike in a burst, which was followed by a second spike with an ISI of ≤10 ms. The coefficient of variation (CV2) was calculated to detect irregular firing based on the variation in the ISIs. CV2 was calculated as described previously [45] by assessing the SD and mean firing for two adjacent ISIs (CV2 = 2 (ISI2−ISI1)/(ISI2+ISI1)). The CV2 for each pair of adjacent ISIs was plotted against the mean of those two ISIs. Small CV2 values indicate regular firing, whereas large CV2 values (≥1) indicate irregular firing.

4.6. Drugs and Drug Application by Microdialysis

A 5-HT2C receptor agonist (WAY161503), a 5-HT2C receptor antagonist (SB242084), and a CRF1 receptor antagonist (NBI27914) were purchased from Tocris Bioscience. Several hours before the start of the electrophysiological recordings, a microdialysis probe (CMA11/Microdialysis; 250 µm membrane diameter; 1 mm membrane length) was lowered vertically into the BLA, ipsilateral to the recording electrode, using the following coordinates: 2.5 mm caudal to bregma, 4.8 mm lateral to midline, 9.0 mm depth. The distance between the microdialysis probe and recording electrode was ~0.5 mm. Before each drug application, artificial cerebrospinal fluid (ACSF) was pumped through the microdialysis fiber for about 1 h at a rate of 5 µL/min to establish equilibrium in the tissue. The microdialysis probe was connected to an infusion pump (Harvard) using PE-50 tubing. The ACSF contained (in mM) 125.0 NaCl, 2.6 KCl, 2.5 NaH2PO4, 1.3 CaCl2, 0.9 MgCl2, 21.0 NaHCO3, and 3.5 glucose oxygenated and equilibrated to pH ± 7.4. Drugs were dissolved in ACSF on the day of the experiment at a concentration
of 100 times that was predicted to be needed based on data from our previous studies [36,48,61,91,92] and data in the literature [93–95]. Drugs were administered into the BLA at a rate of 5 µL/min.

4.7. Verification of Recording Site

At the end of each experiment, the recording site in the CeA was marked by an electrolytic lesion with DC (250 mA for 3 min) injected through the recording electrode. The brain was removed and submerged in 10% formalin and potassium ferrocyanide. Tissues were stored in 30% sucrose before they were frozen sectioned at 50 µm and stained with hematoxylin and eosin. The boundaries of the different amygdala nuclei were easily identified under the microscope. Lesion/recording sites were verified histologically and plotted on standard diagrams.

4.8. Statistical Analysis

All averaged values are given as the mean ± SE. Statistical significance was accepted at the level p < 0.05. GraphPad Prism 5.0 software was used for all statistical analyses. Statistical analysis was performed on the raw data.

Author Contributions: G.J. carried out the experiments, analyzed the data, created figures, and provided a first draft of the manuscript. V.N. conceived the study, developed the experimental design, assisted with data analysis and presentation, and finalized the manuscript.

Funding: This research was funded by the National Institutes of Health (NIH) grants NS081121, NS038261, and NS106902.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Heinricher, M.M.; Tavares, I.; Leith, J.L.; Lumb, B.M. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res. Rev. 2009, 60, 214–225. [CrossRef] [PubMed]
2. Ossipov, M.H.; Dussor, G.O.; Porreca, F. Central modulation of pain. J. Clin. Investig. 2010, 120, 3779–3787. [CrossRef] [PubMed]
3. Sommer, C. Is serotonin hyperalgesic or analgesic? Curr. Pain Headache Rep. 2006, 10, 101–106. [CrossRef] [PubMed]
4. Suzuki, R.; Rygh, L.J.; Dickenson, A.H. Bad news from the brain: Descending 5-HT pathways that control spinal pain processing. Trends Pharmacol. Sci. 2004, 25, 613–617. [CrossRef] [PubMed]
5. Bockaert, J.; Claeyesen, S.; Bécamel, C.; Dumuis, A.; Marin, P. Neuronal 5-HT metabotropic receptors: Fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006, 326, 553–572. [CrossRef] [PubMed]
6. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. Serotonin Sleep Mol. Funct. Clin. Asp. 2008, 195, 155–182.
7. Millán, M.; Marin, P.; Bockaert, J.; Mannoury-lacour, C. Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions. Trends Pharmacol. Sci. 2008, 29, 454–464. [CrossRef] [PubMed]
8. Dworkin, R.H.; O’Connor, A.B.; Audette, J.; Baron, R.; Gourlay, G.K.; Haanpää, M.L.; Kent, J.L.; Krane, E.J.; Lebel, A.A.; Levy, R.M.; et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Mayo Clin. Proc. 2010, 85, S3–S14. [CrossRef] [PubMed]
9. Finnerup, N.; Attal, N.; Haroutounian, S. Pharmacotherapy for Neuropathic Pain in Adults: A Systematic Review and Meta-Analysis. J. Vasc. Surg. 2015, 62, 1091. [CrossRef]
10. Lee, Y.C.; Chen, P.P. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin. Pharmacother. 2010, 11, 2813–2825. [CrossRef] [PubMed]
11. Napoletano, F.; Lionetto, L.; Martelletti, P. Sumatriptan in clinical practice: Effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opin. Pharmacother. 2014, 15, 303–305. [CrossRef] [PubMed]
12. Negro, A.; Koverech, A.; Martelletti, P. Serotonin receptor agonists in the acute treatment of migraine: A review on their therapeutic potential. J. Pain Res. 2018, 11, 515–526. [CrossRef] [PubMed]
13. Jensen, N.H.; Cremers, T.I.; Sotty, F. Therapeutic Potential of 5-HT2C Receptor Ligands. Sci. World J. 2010, 10, 1870–1885. [CrossRef] [PubMed]
14. Brach-Andersen, C.; Møller, M.U.; Christiansen, L.; Thinggaard, M.; Otto, M.; Brosen, K.; Sindrup, S.H. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). *Eur. J. Clin. Pharmacol.* 2011, 67, 1131–1137. [CrossRef] [PubMed]

15. Vicente, M.A.; Zangrossi, H. Involvement of 5-HT2C and 5-HT1A receptors of the basolateral nucleus of the amygdala in the anxiolytic effect of chronic antidepressant treatment. *Neuropsychopharmacology* 2014, 79, 127–135. [CrossRef] [PubMed]

16. Phelps, E.A.; LeDoux, J.E. Contributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior. *Neuron* 2005, 48, 175–187. [CrossRef]

17. Clemett, D.A.; Punhani, T.; Duxon, T.P.; Fone, K.C. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. *Neuropsychopharmacology* 2000, 39, 123–132. [CrossRef]

18. Pompeiano, M.; Palacios, J.; Mengod, G. Distribution of the serotonin 5-HT2 receptor family mRNAs: Comparison between 5-HT2A and 5-HT2C receptors. *Mol. Brain Res.* 1994, 23, 163–178. [CrossRef]

19. Bocchio, M.; McHugh, S.B.; Bannerman, D.M.; Sharp, T.; Capogna, M. Serotonin, Amygdala and Fear: Assembling the Puzzle. *Front. Neural Circuits* 2016, 10, 24. [CrossRef]

20. Ma, Q.; Yin, G.; Ai, M.; Han, J. Serotonergic projections from the nucleus raphe dorsalis to the amygdala in the rat. *Neurosci. Lett.* 1991, 134, 21–24. [CrossRef]

21. Christianson, J.P.; Ragole, T.; Amat, J.; Greenwood, B.N.; Strong, P.V.; Paul, E.D.; Fleshner, M.; Watkins, L.R.; Maier, S.F. 5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. *Biol. Psychiatry* 2010, 67, 339–345. [CrossRef]

22. Funada, M.; Hara, C. Differential effects of psychological stress on activation of the 5-hydroxytryptamine- and dopamine-containing neurons in the brain of freely moving rats. *Brain Res.* 2001, 901, 247–251. [CrossRef]

23. Macedo, C.E.; Martinez, R.C.R.; Silva, M.A.D.S.; Brandào, M.L. Increases in extracellular levels of 5-HT and dopamine in the basolateral, but not in the central, nucleus of amygdala induced by aversive stimulation of the inferior colliculus. *Eur. J. Neurosci.* 2005, 21, 1131–1138. [CrossRef]

24. Kimura, A.; Stevenson, P.L.; Carter, R.N.; MacColl, G.; French, K.L.; Simons, J.P.; Al-Shawi, R.; Kelly, V.; Chapman, K.E.; Holmes, M.C. Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. *Eur. J. Neurosci.* 2009, 30, 299–306. [CrossRef]

25. Li, Q.; Luo, T.; Jiang, X.; Wang, J. Anxiolytic effects of 5-HT1A receptors and anxiogenic effects of 5-HT2C receptors in the amygdala of mice. *Neuropsychopharmacology* 2012, 42, 474–484. [CrossRef] [PubMed]

26. Heisler, L.K.; Zhou, L.; Baija, P.; Hsu, J.; Tecott, L.H. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. *Genes Brain Behav.* 2007, 6, 491–496. [CrossRef]

27. Campbell, B.M.; Merchant, K.M. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. *Brain Res.* 2003, 993, 1–9. [CrossRef]

28. Vicente, M.A.; Zangrossi, H. Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration. *Int. J. Neuropsychopharmacol.* 2012, 15, 389–400. [CrossRef] [PubMed]

29. De Mello Cruz, A.P.; Pinheiro, G.; Alves, S.H.; Ferreira, G.; Mendes, M.; Faria, L.; Macedo, C.E.; Motta, V.; Landeira-Fernandez, J. Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze. *Psychopharmacology* 2005, 182, 345–354. [CrossRef]

30. Neugebauer, V. Amygdala pain mechanisms. *Handb. Exp. Pharmacol.* 2015, 227, 261–284.

31. Neugebauer, V.; Li, W.; Bird, G.C.; Han, J.S. The amygdala and persistent pain. *Neuroscientist* 2004, 10, 221–234. [CrossRef] [PubMed]

32. Thompson, J.M.; Neugebauer, V. Amygdala Plasticity and Pain. *Pain Res. Manag.* 2017, 2017, 8296501. [CrossRef]

33. Adedoyin, M.O.; Vicini, S.; Neale, J.H. Endogenous N-acetylaspartylglutamate (NAAG) inhibits synaptic plasticity/transmission in the amygdala in a mouse inflammatory pain model. *Mol. Pain* 2010, 6, 60. [CrossRef] [PubMed]

34. Bird, G.C.; Lash, L.L.; Han, J.S.; Zou, X.; Willis, W.D.; Neugebauer, V. Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurons. *J. Physiol.* 2005, 564, 907–921. [CrossRef] [PubMed]
35. Cheng, S.J.; Chen, C.C.; Yang, H.W.; Chang, Y.T.; Bai, S.W.; Chen, C.C.; Yen, C.T.; Min, M.Y. Role of Extracellular Signal-Regulated Kinase in Synaptic Transmission and Plasticity of a Noxious Input on Capsular Central Amygdaloid Neurons in Normal and Acid-Induced Muscle Pain Mice. *J. Neurosci.* 2011, 31, 2258–2270. [CrossRef] [PubMed]

36. Fu, Y.; Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. *J. Neurosci.* 2008, 28, 3861–3876. [CrossRef] [PubMed]

37. Han, J.S.; Li, W.; Neugebauer, V. Critical Role of Calcitonin Gene-Related Peptide 1 Receptors in the Amygdala in Synaptic Plasticity and Pain Behavior. *J. Neurosci.* 2005, 25, 10717–10728. [CrossRef] [PubMed]

38. Ji, G.; Li, Z.; Neugebauer, V. Reactive oxygen species mediate visceral pain–related amygdala plasticity and behaviors. *Pain* 2015, 156, 825–836. [CrossRef] [PubMed]

39. Neugebauer, V.; Li, W.; Bird, G.C.; Bhave, G.; Gereau, R.W. Synaptic Plasticity in the Amygdala in a Model of Arthritic Pain: Differential Roles of Metabotropic Glutamate Receptors 1 and 5. *J. Neurosci.* 2003, 23, 52–63. [CrossRef]

40. Ren, W.; Kiritoshi, T.; Gregoire, S.; Ji, G.; Guerrini, R.; Calo, G.; Neugebauer, V. Neuropeptide S: A novel regulator of pain-related amygdala plasticity and behaviors. *J. Neurophysiol.* 2013, 110, 1765–1781. [CrossRef]

41. Shinohara, K.; Watabe, A.M.; Nagase, M.; Okutsu, Y.; Takahashi, Y.; Kurihara, H.; Kato, F. Essential role of endogenous calcitonin gene-related peptide in pain-associated plasticity in the central amygdala. *Eur. J. Neurosci.* 2017, 46, 2149–2160. [CrossRef] [PubMed]

42. Sugimura, Y.K.; Takahashi, Y.; Watabe, A.M.; Kato, F. Synaptic and network consequences of monosynaptic nociceptive inputs of parabrachial nucleus origin in the central amygdala. *J. Neurophysiol.* 2016, 115, 2721–2739. [CrossRef] [PubMed]

43. Gonçalves, L.; Silva, R.; Pinto-Ribeiro, F.; Pêgo, J.M.; Bessa, J.M.; Pertovaara, A.; Sousa, N.; Almeida, A. Neurogenic pain is associated with depressive behaviour and induces neuroplasticity in the amygdala of the rat. *Exp. Neurol.* 2008, 213, 48–56. [CrossRef]

44. Ikeda, R.; Takahashi, Y.; Inoue, K.; Kato, F. NMDA receptor-independent synaptic plasticity in the central amygdala in the rat model of neuropathic pain. *Pain* 2007, 127, 161–172. [CrossRef] [PubMed]

45. Ji, G.; Zhang, W.; Mahimainathan, L.; Narasimhan, M.; Kiritoshi, T.; Fan, X.; Wang, J.; Green, T.A.; Neugebauer, V. 5-HT2C Receptor Knockdown in the Amygdala Inhibits Neuropathic-Pain-Related Plasticity and Behaviors. *J. Neurosci.* 2017, 37, 1378–1393. [CrossRef] [PubMed]

46. Nakao, A.; Takahashi, Y.; Nagase, M.; Ikeda, R.; Kato, F. Role of capsaicin-sensitive C-fiber afferents in neuropathic pain-induced synaptic potentiation in the nociceptive amygdala. *Mol. Pain* 2012, 8, 51. [CrossRef] [PubMed]

47. Gonçalves, L.; Dickenson, A.H. Asymmetric time-dependent activation of right central amygdala neurones in rats with peripheral neuropathy and pregabalin modulation. *Eur. J. Neurosci.* 2012, 36, 3204–3213. [CrossRef] [PubMed]

48. Ji, G.; Neugebauer, V. Differential Effects of CRF1 and CRF2 Receptor Antagonists on Pain-Related Sensitization of Neurons in the Central Nucleus of the Amygdala. *J. Neurophysiol.* 2007, 97, 3893–3904. [CrossRef] [PubMed]

49. Ji, G.; Neugebauer, V. Hemispheric Lateralization of Pain Processing by Amygdala Neurons. *J. Neurophysiol.* 2009, 102, 2253–2264. [CrossRef]

50. Ji, G.; Neugebauer, V. Reactive Oxygen Species Are Involved in Group I mGlur-Mediated Facilitation of Nociceptive Processing in Amygdala Neurons. *J. Neurophysiol.* 2010, 104, 218–229. [CrossRef]

51. Li, W.; Neugebauer, V. Block of NMDA and non-NMDA receptor activation results in reduced background and evoked activity of central amygdala neurons in a model of arthritic pain. *Pain* 2004, 110, 112–122. [CrossRef] [PubMed]

52. Li, W.; Neugebauer, V. Differential Roles of mGlur1 and mGlur5 in Brief and Prolonged Nociceptive Processing in Central Amygdala Neurons. *J. Neurophysiol.* 2004, 91, 13–24. [CrossRef] [PubMed]

53. Li, W.; Neugebauer, V. Differential Changes of Group II and Group III mGlur Function in Central Amygdala Neurons in a Model of Arthritic Pain. *J. Neurophysiol.* 2006, 96, 1803–1815. [CrossRef] [PubMed]

54. Medina, G.; Ji, G.; Grégoire, S.; Neugebauer, V. Nasal Application of Neuropeptide S Inhibits Arthritis Pain-Related Behaviors through an Action in the Amygdala. *Mol. Pain* 2014, 10, 32. [CrossRef]

55. Neugebauer, V.; Li, W. Differential Sensitization of Amygdala Neurons to Afferent Inputs in a Model of Arthritic Pain. *J. Neurophysiol.* 2003, 89, 716–727. [CrossRef]
56. Ji, G.; Sun, H.; Fu, Y.; Li, Z.; Pais-Vieira, M.; Galhardo, V.; Neugebauer, V. Cognitive impairment in pain through amygdala-driven prefrontal cortical deactivation. *J. Neurosci.* 2010, 30, 5451–5464. [CrossRef]
57. Chen, A.; Hough, C.; Li, H. Serotonin type II receptor activation facilitates synaptic plasticity via n-methyl-d-aspartate-mediated mechanism in the rat basolateral amygdala. *Neuroscience* 2003, 119, 53–63. [CrossRef]
58. Sengupta, A.; Bocchio, M.; Bannerman, D.M.; Sharp, T.; Capogna, M. Control of Amygdala Circuits by 5-HT Neurons via 5-HT and Glutamate Cotransmission. *J. Neurosci.* 2017, 37, 1785–1796. [CrossRef]
59. Guo, J.D.; O’Flaherty, B.M.; Rainnie, D.G. Serotonin gating of cortical and thalamic glutamate inputs onto principal neurons of the basolateral amygdala. *Neuropharmacology* 2017, 126, 224–232. [CrossRef]
60. Rainnie, D.G. Serotonergic Modulation of Neurotransmission in the Rat Basolateral Amygdala. *J. Neurophysiol.* 1999, 82, 69–85. [CrossRef]
61. Grégoire, S.; Neugebauer, V. 5-HT2CR blockade in the amygdala conveys analgesic efficacy to SSRIs in a rat model of arthritis pain. *Mol. Pain* 2013, 9, 41. [CrossRef] [PubMed]
62. Neugebauer, V.; Li, W. Processing of Nociceptive Mechanical and Thermal Information in Central Amygdala Neurons with Knie-Joint Input. *J. Neurophysiol.* 2002, 87, 103–112. [CrossRef] [PubMed]
63. Anastasio, N.C.; Stutz, S.J.; Fink, L.H.; Swinford-Jackson, S.E.; Sears, R.M.; DiLeone, R.J.; Rice, K.C.; Moeller, E.G.; Cunningham, K.A. Serotonin (5-HT) 5-HT2A Receptor (5-HT2AR)-5-HT2CR Imbalance in Medial Prefrontal Cortex Associates with Motor Impulsivity. *ACS Chem. Neurosci.* 2015, 6, 1248–1258. [CrossRef] [PubMed]
64. Anastasio, N.C.; Stutz, S.J.; Fox, R.G.; Sears, R.M.; Emeson, R.B.; DiLeone, R.J.; O’Neil, R.T.; Fink, L.H.; Li, D.; Green, T.A.; et al. Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. *Neuropsychopharmacology* 2014, 39, 370–382. [CrossRef] [PubMed]
65. Wold, E.A.; Wild, C.T.; Cunningham, K.A.; Zhou, J. Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development. *Curr. Top. Med. Chem.* 2019, 19, 1. [CrossRef] [PubMed]
66. Sant’Ana, A.B.; Vilela-Costa, H.H.; Vicente, M.A.; Hernandez, P.M.; De Andrade, T.G.C.S.; Zangrossi, H. Role of 5-HT2C receptors of the dorsal hippocampus in the modulation of anxiety- and panic-related defensive responses in rats. *Neuropharmacology* 2019, 148, 311–319. [CrossRef] [PubMed]
67. Asan, E.; Yilmazer-Hanke, D.; Eliava, M.; Hantsch, M.; Lesch, K.P.; Schmitt, A. The Corticotropin-Releasing Factor (CRF)-system and monoaminergic afferents in the central amygdala: Investigations in different mouse strains and comparison with the rat. *Neuroscience* 2005, 131, 953–967. [CrossRef] [PubMed]
68. Bale, T.L.; Vale, W.W. CRF and CRF receptors: Role in stress responsivity and other behaviors. *Annu. Rev. Pharmacol. Toxicol.* 2004, 44, 525–557. [CrossRef]
69. Gray, T.S. Amygdaloid CRF Pathways: Role in Autonomic, Neuroendocrine, and Behavioral Responses to Stress. *Annu. N. Y. Acad. Sci.* 1993, 697, 53–60. [CrossRef]
70. Pomerenze, M.B.; Millan, E.Z.; Hopf, F.W.; Keiflin, R.; Maiya, R.; Blasio, A.; Dadgar, J.; Kharazia, V.; De Guglielmo, G.; Crawford, E.; et al. A Transgenic Rat for Investigating the Anatomy and Function of Corticotropin Releasing Factor Circuits. *Front. Mol. Neurosci.* 2015, 9, 5626. [CrossRef]
71. Reul, J.M.; Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr. Opin. Pharmacol.* 2002, 2, 23–33. [CrossRef]
72. Chen, Y.; Brunson, K.L.; Cariaga, W.; Baram, T.Z.; Müller, M.B. Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 (CRF1)-like immunoreactivity in the mouse brain: Light microscopy analysis using an antibody directed against the C-terminus. *J. Comp. Neurol.* 2000, 420, 305–323. [CrossRef]
73. Greenwood-Van Meerveld, B.; Johnson, A.C.; Schulkin, J.; Myers, D.A. Long-term expression of corticotropin-releasing factor (CRF) in the paraventricular nucleus of the hypothalamus in response to an acute colonic inflammation. *Brain Res.* 2006, 1071, 91–96. [CrossRef] [PubMed]
74. Lariviere, W.R.; Melzack, R. The role of corticotropin-releasing factor in pain and analgesia. *Pain* 2000, 84, 1–12. [CrossRef]
75. McNally, G.; Akil, H.; McNally, G. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. *Neuroscience* 2002, 112, 605–617. [CrossRef]
76. Sinniger, V.; Porcher, C.; Mouchet, P.; Juhem, A.; Bonaz, B. c-fos and CRF receptor gene transcription in the brain of acetic acid-induced somato-visceral pain in rats. *Pain* **2004**, *110*, 738–750. [CrossRef] [PubMed]

77. Ulrich-Lai, Y.M.; Xie, W.; Meij, J.T.; Dolgas, C.M.; Yu, L.; Herman, J.P. Limbic and HPA axis function in an animal model of chronic neuropathic pain. *Physiol. Behav.* **2006**, *88*, 67–76. [CrossRef] [PubMed]

78. Fernandez, S.P.; Cauli, B.; Cabezas, C.; Muzerelle, A.; Poncer, J.C.; Gaspar, P. Multiscale single-cell analysis reveals unique phenotypes of raphe 5-HT neurons projecting to the forebrain. *Brain Struct. Funct.* **2016**, *221*, 4007–4025. [CrossRef]

79. Muller, J.F.; Mascagni, F.; McDonald, A.J. Serotonin-immunoreactive axon terminals innervate pyramidal cells and interneurons in the rat basolateral amygdala. *J. Comp. Neurol.* **2007**, *505*, 314–335. [CrossRef]

80. Parent, A.; Descarries, L.; Beaudet, A. Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. *Neuroscience* **1981**, *6*, 115–138. [CrossRef]

81. Pockros-Burgess, L.A.; Pentkowski, N.S.; Der-Ghazarian, T.; Neisewander, J.L. Effects of the 5-HT2C receptor agonist CP809101 in the amygdala on reinstatement of cocaine-seeking behavior and anxiety-like behavior. *Int. J. Neuropsychopharmacol.* **2014**, *17*, 1751–1762. [CrossRef] [PubMed]

82. Moya, P.R.; Fox, M.A.; Jensen, C.L.; Laporte, J.L.; French, H.T.; Wendland, J.R.; Murphy, D.L. Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice. *BMC Pharmacol.* **2011**, *11*, 3. [CrossRef] [PubMed]

83. Corder, G.; Ahanonu, B.; Grewe, B.F.; Wang, D.; Schnitzer, M.J.; Scherrer, G. An amygdalar neural ensemble that encodes the unpleasantness of pain. *Science* **2019**, *363*, 276–281. [CrossRef] [PubMed]

84. Veinante, P.; Yalcin, I.; Barrot, M. The amygdala between sensation and affect: A role in pain. *J. Mol. Psychiatry* **2013**, *3*, 9. [CrossRef]

85. Jasmin, L.; Rabkin, S.D.; Granato, A.; Boudah, A.; Ohara, P.T. Analgesia and hyperalgesia from 5-HT2C receptor agonist-induced synaptic transmission and pain responses. *Mol. Pain* **2013**, *9*, 2. [CrossRef]

86. Heinricher, M.M.; McGarvaughty, S. Microinjection of morphine into various amygdaloid nuclei differentially affects nociceptive responsiveness and RVM neuronal activity. *Diabetes Nerv. Syst.* **2002**, *96*, 153–162.

87. Ji, G.; Fu, Y.; Adwanikar, H.; Neugebauer, V. Non-pain-related CRF1 activation in the amygdala facilitates synaptic transmission and pain responses. *Mol. Pain* **2013**, *9*, 2. [CrossRef]

88. Fletcher, P.J.; Tampakeras, M.; Sinyard, J.; Sassi, A.; Isaac, M.; Higgins, G.A. Characterizing the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice. *Neuropsychopharmacology* **2009**, *57*, 259–267. [CrossRef] [PubMed]

89. Bennett, G.J.; Chung, J.M.; Honore, M.; Seltzer, Z. Models of Neuropathic Pain in the Rat. *Curr. Protoc.* **2002**, *45*, 81–9. [CrossRef] [PubMed]

90. Ji, G.; Yakhnitsa, V.; Kiritoshi, T.; Presto, P.; Neugebauer, V. Fear extinction learning ability predicts neuropathic pain behaviors and amygdala activity in male rats. *Mol. Pain* **2018**, *14*, 1744806918804441. [CrossRef]

91. Bennet, G.J.; Chung, J.M.; Honore, M.; Seltzer, Z. Models of Neuropathic Pain in the Rat. *Curr. Protoc.* **2003**, *45*, 81–9. [CrossRef] [PubMed]

92. Ji, G.; Yakhnitsa, V.; Kim, A.K.; Presto, P.; Neugebauer, V. Fear extinction learning ability predicts neuropathic pain behaviors and amygdala activity in male rats. *Mol. Pain* **2018**, *14*, 1744806918804441. [CrossRef]

93. Cunningham, K.A.; Fox, R.G.; Anastasio, N.C.; Bubar, M.J.; Stutz, S.J.; Moeller, F.G.; Gilbertson, S.R.; Rosenzweig-Lipson, S. Selective serotonin 5-HT2C receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. *Neuropsychopharmacology* **2011**, *61*, 513–523. [CrossRef] [PubMed]

94. Pentkowski, N.S.; Duke, F.D.; Weber, S.M.; APockros, L.; Teer, A.P.; Hamilton, E.C.; Thiel, K.J.; Neisewander, J.L. Stimulation of Medial Prefrontal Cortex Serotonin 2C (5-HT2C) Receptors Attenuates Cocaine-Seeking Behavior. *Neuropsychopharmacology* **2010**, *35*, 2037–2048. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).